Structure-based Discovery of a Non-competitive FTO Inhibitor Bound to a Cryptic Site at the Domain Interface
Aayushi Singh1, Francesco Pettini2, Beatrice Gianibbi3
1Department of Chemistry, Iowa State University, Ames, IA, USA.
Abstract:
The fat mass and obesity-associated fatso (FTO) protein is a member of the AlkB family of dioxygenases whose overexpression links to several metabolic diseases, including obesity, type 2 diabetes, Alzheimer's, and various types of cancer. FTO is an important target for pharmaceutical research, and several selective and non-selective competitive inhibitors have been developed against the enzyme. However, given the competitive nature of the available inhibitors, obtaining complete subfamily selectivity still presents an unresolved challenge. Here, we describe the discovery of a molecular scaffold for selective inhibition of FTO, which resulted from high throughput virtual screening targeted at FTO cryptic pockets. Analysis of the FTO-inhibitor interaction by solution NMR, molecular dynamics simulations, and enzyme kinetic assays shows that, differently from the FTO inhibitors developed so far, our molecule binds to a cryptic site between the FTO structural domains, and modulates the enzyme function non-competitively by perturbing the binding pose of the α-ketoglutarate and nucleic acid substrates. Since FTO is the only member of the AlkB family that presents multiple structural domains, we expect further development of this allosteric molecule to result in a new family of highly selective FTO inhibitors that can be used alone or in combination with pre-existing compounds to improve their potency and selectivity.
Insights
Researchers discovered a novel molecular scaffold that selectively inhibits the fat mass and obesity-associated (FTO) protein. This allosteric inhibitor targets a cryptic site, offering a new strategy for treating metabolic diseases and cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- The fat mass and obesity-associated (FTO) protein is implicated in obesity, type 2 diabetes, Alzheimer's, and cancer.
- Current FTO inhibitors are competitive and face challenges in achieving subfamily selectivity.
- Developing selective FTO inhibitors is crucial for pharmaceutical research.
Purpose of the Study:
- To discover a novel molecular scaffold for selective FTO inhibition.
- To characterize the binding mode and inhibitory mechanism of the new scaffold.
- To explore a new therapeutic strategy for FTO-related diseases.
Main Methods:
- High-throughput virtual screening of FTO cryptic pockets.
- Solution Nuclear Magnetic Resonance (NMR) spectroscopy.
- Molecular dynamics simulations and enzyme kinetic assays.
Main Results:
- Identified a molecular scaffold that binds to a cryptic site between FTO structural domains.
- Demonstrated non-competitive inhibition by perturbing substrate binding.
- Confirmed FTO's unique multi-domain structure among AlkB family members.
Conclusions:
- The discovered molecule represents a novel allosteric inhibitor scaffold for FTO.
- This approach offers a promising avenue for developing highly selective FTO inhibitors.
- Further development could lead to improved therapeutic strategies for metabolic diseases and cancer.
More Related Videos
Related Concept Videos
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Conserved Binding Sites
Protein-protein Interfaces
Protein-Protein Interfaces
Ligand Binding and Linkage
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...


